Anti-alk antibodies suitable for treating metastatic cancers or tumors
MY164890A
Stable and soluble antibodies inhibiting tnfa
WO2008006235A2
Scfv antibodies which pass epithelial and/or endothelial layers
CN101443361A
Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
WO2006133588A1
ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS
WO2006131013A2
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
MX342638B
Stable and soluble antibodies inhibiting tnfî±.
ZA200710109B
Stable and soluble antibodies inhibiting TNFALPHA
WO2006111035A1
Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
EP1790345A1
Triazin beta-secretase inhibitors
EP1734039A1
Aryl urea compounds as BETA-secretase inhibitors
WO2005120513A1
Protein kinase inhibitors
EP1715059A1
Method for the identification of possibly harmful receptor tyrosine kinase (RTK) mutations and of inhibitors or medication directed against RTK mutants
EP1613751A1
Method for the construction of randomized gene sequence libraries in cells
US2006068388A1
Method for the identification of modulators of a secretase activity
CA2396534A1
Intrabodies with defined framework that is stable in a reducing environment and applications thereof
CA2401155A1
Method for identify polypeptides with protease activity
